$AEZS Target PTs 3.50-5.50-15

Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-19 vaccine.
The vaccine is currently in preclinical development and was invented at the Julius-Maximilians-University in Wuerzburg.
Additionally, the Company has entered into a research agreement with the University to conduct supplementary research activities and preclinical development studies on the potential vaccine.
The vaccine technology uses the approved typhoid fever vaccine Salmonella Typhi Ty21a as a carrier strain. It has the potential to be an orally active, live-attenuated bacterial vaccine to prevent COVID-19 infection.
The Company will pay an up-front payment of €140,000, certain milestones payments, sales milestones, and a percentage of any sub-licensing revenue.
Recently, AEZS obtained an exclusive license from The University of Sheffield, the U.K., to parathyroid hormone fusion polypeptides, which will initially be studied for primary hypoparathyroidism.
Price Action: AEZS shares increased 15.3% at $1.36 in premarket trading on the last check Monday.